Alpha-bloquants

<p>Applications An optically active metabolite of Carvedilol (C184625), a nonselective ß-adrenergic blocker with α1-blocking activity. [α]D= -18.7 (c= 0.1 methanol)<br> Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package<br>References Sponer, G., et al.: J. Cardiovasc. Pharmacol., 9, 317 (1987), Fujimaki, M., et al.: Xenobiotica, 20, 1025 (1990), Ruffolo, R., et al.: Eur. J. Clin. Pharmacol., 38, S82 (1990), Clohs, L., et al.: J. Pharm. Biomed. Anal., 31, 407 (2003),<br></p>

<p>Applications (αR)-4-Methoxy-α-methyl-N-[(1R)-1-phenylethyl]benzeneethanamine is used in the symthesis of Formoterol (F693400).<br>References Hett, R., et al.: Tetrahedron Lett., 38, 1125 (1997),<br></p>

<p>N-(4-Amino-6,7-dimethoxyquinazol-2-yl)-N-methylpropylenediamine formamide hydrochloride is an impurity in the synthesis of N-(4-amino-6,7-dimethoxyquinazol-2-yl)-N'-methylpropylenediamine formamide hydrochloride. It is a white solid that can be used as an analytical reference standard for HPLC. It has been detected in the urine of people taking this drug and can be used to identify the presence of this drug in urine samples.</p>

<p>1-[4-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-1-piperazinyl]-2-hydroxy-1-pentanone (DMPP) is an analog of the antiarrhythmic drugs flecainide and propafenone. It has the same effects as these drugs, but with a longer duration of action. DMPP is a racemic mixture of two enantiomers, one of which is active against arrhythmias and the other inactive. The drug binds to the beta subunit of voltage gated potassium channels in cardiac muscle cells, preventing the flow of current through these channels. This results in prolongation of the action potential and suppression of arrhythmias. DMPP also inhibits cellulase activity and may be used as an agent for treatment of bacterial infections caused by methicillin resistant Staphylococcus aureus (MRSA).</p>

<p>6,7-Dimethoxy-2-[4-[(tetrahydro-2-furanyl)carbonyl]-1-piperazinyl]-4(3H)-quinazolinone is a drug product. It is an analytical standard for the impurity of CAS No. 1177261-73-2. This compound has been synthesized by custom synthesis and its purity is high. The compound has been used in research and development of drugs, pharmacopoeia, HPLC standards, and other related fields.</p>

<p>1,4-Di-2-furoylpiperazine is a synthetic compound that has been shown to have anti-inflammatory and analgesic properties. It was originally developed as a pharmaceutical drug candidate for the treatment of arthritis and other inflammatory disorders. 1,4-Di-2-furoylpiperazine is an impurity in the synthesis of the drug product diclofenac. The compound is also found as a metabolite in humans after oral administration of diclofenac. 1,4-Di-2-furoylpiperazine binds to protein and inhibits protein synthesis by preventing amino acid incorporation into proteins. It also has nicotinic effects on acetylcholine binding sites and can be used as an analytical standard for HPLC analysis of drugs containing this molecule.</p>

<p>2,2'-(1,4-Piperazinediyl)bis[6,7-dimethoxy-4-quinazolinamine] is a chemical compound that is used as a lead to develop new drugs against malaria. It inhibits the growth of plasmodium falciparum and has been shown to be active in high-throughput screening assays. 2,2'-(1,4-Piperazinediyl)bis[6,7-dimethoxy-4-quinazolinamine] may serve as an active molecule for the treatment of malaria in combination with other antiplasmodial agents. The drug discovery process prioritized this compound because it is an asexual stage inhibitor and has gametocyte inhibitory activities.</p>

<p>N-(4-Amino-6,7-dimethoxyquinazol-2-yl)-N-methylpropylenediamine hydrochloride is an impurity that can be found in some commercially available drugs. It is a metabolite of the drug N-(4-amino-6,7-dimethoxyquinazol-2-yl)propylenediamine and is used as a reference standard for HPLC analysis. This compound has been shown to have antiplatelet activities.</p>

<p>N2-Methyl alfuzosin-D7 is a drug product that belongs to the group of alfuzosin, which is a selective inhibitor of the enzyme phosphodiesterase type 5 (PDE5) and is used for the treatment of benign prostatic hyperplasia. It has been designed to reduce the risk of adverse effects associated with other PDE5 inhibitors, such as erectile dysfunction and urinary retention. N2-Methyl alfuzosin-D7 has been shown to be effective in animal studies and in vitro experiments. However, its metabolism remains unknown.</p>

<p>4-(4-Amino-6-hydroxy-7-methoxy-2-quinazolinyl)-1-piperazinyl](tetrahydro-2-furanyl)-methanone (CAS No. 105356-89-6) is a synthetic impurity standard used in the manufacture of various drugs. Impurities are substances that exist in a mixture with the desired product, but are not an intentional part of that product. Synthetic impurities are created during the synthesis process and are not found in nature. This substance has been shown to be metabolized by cytochrome P450 enzymes and glutathione reductase, and is excreted through urine and bile. It also binds to markers expressed at high levels in Mycobacterium tuberculosis strains (e.g., ESX-1 secretion system protein) and inhibits cell growth in culture.</p>

<p>1-[4-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-1-piperazinyl]-5-hydroxy-1-pentanone is a drug product that is used as an HPLC standard. It is a natural metabolite of the drug product 1-[4-(4-Amino-6,7-dimethoxyquinazolinyl)-1piperazinyl]-5hydroxypentane. The synthesis of this compound has been reported in the literature.<br>The impurity content of this compound meets the pharmacopoeia requirements for an analytical reference standard for API impurities.</p>

<p>Trazodone Impurity A is a drug product that is an impurity standard for Trazodone. It has been classified as a synthetic metabolite and is used in analytical research studies. Trazodone Impurity A has demonstrated niche applications in the pharmaceutical industry, including metabolism studies, pharmacopoeia requirements, and HPLC standards.</p>

<p>2-[3-[4-(3-Chloro-4-ethylphenyl)-1-piperazinyl]propyl]-1,2,4-triazolo[4,3-a]pyridin-3(2H)-one is a research and development impurity standard. Impurities are the substances that are not intentionally added to the drug product but can be generated from the synthesis process or from the raw materials. This substance has been used as a synthetic intermediate in the production of other drugs and as an analytical reference for HPLC analysis. It is used to help develop new drugs by providing data about metabolites and possible toxic effects on humans.</p>

<p>N2-Methyl alfuzosin is an impurity of Alfuzosin, a drug used to treat benign prostatic hyperplasia. It can be used as an HPLC standard for the detection and quantification of Alfuzosin in pharmaceutical products. N2-Methyl alfuzosin is a metabolite of Alfuzosin that is formed by cytochrome P450 3A4. It has been shown to have anti-inflammatory effects, which may be due to its inhibition of prostaglandin synthesis.</p>

<p>Mirtazapine N-oxide is an antidepressant agent that is metabolized to mirtazapine. Mirtazapine N-oxide has been shown to have a linear response in the detection of serotonin in urine samples and has been used for pharmacokinetic studies, optimization, and clinical use. The enantiomer of mirtazapine N-oxide has been shown to be more potent than the racemic mixture. The drug is excreted unchanged into the urine with a half-life of 2 hours. Mirtazapine N-oxide can be detected in plasma for up to 24 hours after oral administration and may accumulate in certain tissues such as liver or kidney. This drug has also been shown to cause death in mice at very high doses.</p>

<p>10-Oxo mirtazapine is a metabolite of the antidepressant drug mirtazapine. It is an impurity in the HPLC standard for mirtazapine and has been shown to be pharmacologically active in animal models. 10-Oxo mirtazapine has also been found to be an impurity in other drugs, such as fluoxetine hydrochloride, but it is not known if it has any activity.</p>

<p>Labetalol EP Impurity C is a synthetic impurity standard that is used to calibrate HPLC columns and for the quantification of labetalol in drug products. Labetalol EP Impurity C is a metabolite of labetalol and has been shown to have similar pharmacological properties. Labetalol EP Impurity C is synthesized by ester hydrolysis. The purity of this compound exceeds 99%.</p>

<p>1,4-Bis[(tetrahydro-2-furanyl)carbonyl]-piperazine is a synthetic drug product. It is used as an analytical standard to help elucidate the metabolic pathway of drugs and their metabolites. This compound has been shown to be metabolized by various enzymes including CYP450, glutathione reductase, and esterases. It can also be synthesized from 1,4-dihydropyridine and 2-furancarboxaldehyde. The physical properties of 1,4-bis[(tetrahydro-2-furanyl)carbonyl]-piperazine are: white powder; mp 178°C; IR max 1710 cm−1 (CO); UV max 221 nm (EtOH). The impurities in this product are: 1-(2H)-Quinolinone (CAS No. 2467-94-1) which may have a maximum concentration</p>

<p>Alfuzosin EP Impurity F hydrochloride is a drug product that is used as an analytical standard for Alfuzosin hydrochloride. It is a natural, synthetic, and impurity standard that exhibits similar chromatographic properties to the API. The CAS number of this impurity is 19216-68-3. This product has a niche market because it is used in metabolism studies. It also exhibits high purity and pharmacopoeia grade quality.</p>